Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase 3 KEYNOTE-189 (ClinicalTrials.gov, NCT02578680; nonsquamous) and...

Full description

Bibliographic Details

Published in:	JTO clinical and research reports Vol. 4; no. 1; p. 100431
Main Authors:	Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.01.2023 Elsevier
Subjects:	Biomarker Hematology, Oncology, and Palliative Medicine Metastatic non‒small-cell lung cancer Original Pembrolizumab Single-gene genetic alterations Tissue tumor mutational burden Pembrolizumab Biomarker Tissue tumor mutational burden Single-gene genetic alterations Metastatic non‒small-cell lung cancer
ISSN:	2666-3643, 2666-3643
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!